Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 165

1.
2.

Variability and impact on design of bioequivalence studies.

Van Peer A.

Basic Clin Pharmacol Toxicol. 2010 Mar;106(3):146-53. doi: 10.1111/j.1742-7843.2009.00485.x. Epub 2009 Nov 11. Review.

3.

Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.

Davit BM, Nwakama PE, Buehler GJ, Conner DP, Haidar SH, Patel DT, Yang Y, Yu LX, Woodcock J.

Ann Pharmacother. 2009 Oct;43(10):1583-97. doi: 10.1345/aph.1M141. Epub 2009 Sep 23.

PMID:
19776300
4.

The bioequivalence of highly variable drugs and drug products.

Midha KK, Rawson MJ, Hubbard JW.

Int J Clin Pharmacol Ther. 2005 Oct;43(10):485-98. Review.

PMID:
16240706
5.

International harmonization of bioequivalence studies and issues shared in common.

Nakai K, Fujita M, Ogata H.

Yakugaku Zasshi. 2000 Nov;120(11):1193-200.

PMID:
11190204
6.

Open questions on bioequivalence: an updated reappraisal.

Marzo A.

Curr Clin Pharmacol. 2007 May;2(2):179-89. Review.

PMID:
18690864
7.

Potential concerns about generic substitution: bioequivalence versus therapeutic equivalence of different amlodipine salt forms.

Meredith PA.

Curr Med Res Opin. 2009 Sep;25(9):2179-89. doi: 10.1185/03007990903116867. Review.

PMID:
19601710
8.

Bioequivalence and other unresolved issues in generic drug substitution.

Meredith P.

Clin Ther. 2003 Nov;25(11):2875-90.

PMID:
14693311
9.

Veterinary drug bioequivalence determination.

Toutain PL, Koritz GD.

J Vet Pharmacol Ther. 1997 Apr;20(2):79-90. Review.

PMID:
9131533
10.

Challenges associated with the evaluation of veterinary product bioequivalence: an AAVPT perspective.

Martinez M, Langston C, Martin T, Conner D.

J Vet Pharmacol Ther. 2002 Jun;25(3):201-20.

PMID:
12081616
11.

[Bioequivalence studies of pharmaceutical preparations].

Vetchý D, Frýbortová K, Rabisková M, Danecková H.

Cas Lek Cesk. 2007;146(5):431-3. Review. Czech.

PMID:
17554963
12.

Quantitative assessment of the switchability of generic products.

Karalis V, Bialer M, Macheras P.

Eur J Pharm Sci. 2013 Nov 20;50(3-4):476-83. doi: 10.1016/j.ejps.2013.08.023. Epub 2013 Aug 24.

PMID:
23981332
13.

Bioequivalence of racemic drugs.

Nerurkar SG, Dighe SV, Williams RL.

J Clin Pharmacol. 1992 Oct;32(10):935-43. Review.

PMID:
1447402
14.

Bioequivalence requirements for generic products.

Nation RL, Sansom LN.

Pharmacol Ther. 1994 Apr-May;62(1-2):41-55. Review.

PMID:
7991647
15.
16.

The new European Medicines Agency guideline on the investigation of bioequivalence.

Morais JA, Lobato Mdo R.

Basic Clin Pharmacol Toxicol. 2010 Mar;106(3):221-5. doi: 10.1111/j.1742-7843.2009.00518.x. Epub 2010 Jan 7. Review.

17.
18.

The transitivity of bioequivalence testing: potential for drift.

Anderson S, Hauck WW.

Int J Clin Pharmacol Ther. 1996 Sep;34(9):369-74.

PMID:
8880284
19.

Bioequivalence and generic prescribing: an industrial view.

Pidgen A.

J Pharm Pharmacol. 1996 Jan;48(1):11-6. Review.

PMID:
8722487
20.

Supplemental Content

Support Center